Author

R. N. McVicar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Organism:mouse· 1

Frequent Co-Authors

S. L. Leibel· 4 shared A. E. Clark· 3 shared A. F. Carlin· 2 shared A. F. Garretson· 2 shared B. A. Croker· 2 shared B. A. Grimmig· 2 shared C. J. Nowell· 2 shared E. M. Kwong· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

S. L. Leibel

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The effects of cell-cell orientation in modeling the hallmarks of lung cancer in vitro

A. S. Espinoza, R. N. McVicar, D. Finlay, R. Murad, K. Vuori, B. A. Grimmig, A. Bush, E. Smith, T. Mandel-Clausen, H. M. McGee, E. Y. Snyder, S. L. Leibel

This study compares 3D tumoroid and 2D cultures of lung cancer cells to assess how cell-cell orientation affects cancer-related features and finds that 3D cultures better mimic primary human lung cancer.

bioRxiv · Dec 30, 2023 · PreprintCancer Biology

The lung employs an intrinsic surfactant-mediated inflammatory response for viral defense

S. L. Leibel, R. N. McVicar, R. Murad, E. M. Kwong, A. E. Clark, A. Alvarado, B. A. Grimmig, R. Nuryyev, R. E. Young, J. C. Lee, W. Peng, Y. P. Zhu, E. Griffis, C. J. Nowell, B. James, , E. Y. Snyder

This study shows that surfactant proteins mediate an intrinsic inflammatory response in the lung to defend against SARS-CoV-2 infection.

bioRxiv · Jan 26, 2023 · PreprintImmunology

Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs

R. T. Schooley, A. F. Carlin, J. R. Beadle, N. Valiaeva, X.-Q. Zhang, A. E. Clark, R. E. McMillian, S. L. Leibel, R. N. McVicar, J. Xie, A. F. Garretson, V. I. Smith, J. A. Murphy, K. Y. Hostetler

This paper develops orally bioavailable lipid prodrugs of Remdesivir that show submicromolar anti-SARS-CoV-2 activity and therapeutic plasma levels in Syrian hamsters.

Antimicrobial Agents and Chemotherapy · Sep 17, 2021Peer-reviewedMicrobiology

The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection

D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch

This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.

bioRxiv · Mar 22, 2021 · PreprintMicrobiology